Welcome to Marit Inngjerdingen's research group:Innate lymphocyte group

Marit Inngjerdingen
Group leader

Background

Our group studies innate lymphocytes, with a particular focus on how NK cells are regulated and how they can be utilized in therapy in context of allo-transplantation and hematological malignancies.

Projects

  • Longitudinal studies of NK cells in pediatric patients with ALL or AML in collaboration with the Department of Children, Oslo University Hospital, where we i) correlate NK cell responses and/or receptor repertoires with disease outcome and ii) evaluate effect of the chemotherapy treatment protocols on NK cells during and after treatment.
  • In-depth mechanistic studies of how leukemia blasts evade and suppress the immune system using in vivorat models of T-ALL and AML. Projects include ex vivo manipulation of NK cells for immunotherapy, and investigations of whether exosomes released from leukemic blasts affect NK cell tumor immunosurveillance.
  • Developmental and functional characterization of NK cell subsets and ILCs in different tissues in the rat, and their regulation of inflammation
  • Evaluation of exosomes as early prognostic markers for risk stratification of pediatric acute leukemia.
  • Characterization of intracellular signaling cascades in human NK cells.

Contact information:
Marit Inngjerdingen, PhD                          
Department of Pharmacology
E-mail: mariti@medisin.uio.no
Tel: +47 95 06 39 29